VANCOUVER, BC / ACCESSWIRE / October 7, 2020 / Core One Labs Inc. (CSE:COOL)(OTCQX:CLABD)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company") is pleased to announce it has entered into a Letter of Intent (the "LOI") dated effective October 1, 2020 to acquire all of the outstanding share capital of Vocan Biotechnologies Inc. ("Vocan").

Vocan is a genetic engineering and biosynthesis research firm developing a proprietary fermentation system for the production of psilocybin API. Vocan's mission is to use science and technology to advance the knowledge of natural-based medicines for the treatment of mental health illnesses, including addictions. Vocan's team of scientists, specializing in protein expression and biosynthetic fermentation, have discovered a patentable method of producing psilocybin, the active ingredient in psychotropic mushrooms, and its technology will produce cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and medical research organizations conducting clinical trials. Vocan's management expects that the unique optimized DNA construct and producer strain will allow for time efficient and cost-effective cGMP API grade psilocybin at commercial scale. Psilocybin production methods developed by Vocan could provide more affordable access to organizations looking to acquire GMP API grade psilocybin.

CEO and Founder of Vocan Biotechnologies

Dr. Robert E.W. Hancock, CEO and Chairman of Vocan, is a leading researcher at the University of British Columbia, a Killam Professor of Microbiology and Immunology, and a Canada Research Chair in Health and Genomics. He is a co-founder of several companies, both private and public, including Migenix, Inimex, ABT Innovations and Sepset Biotherapeutics. He has won major health research awards and is an Officer of the Order of Canada. Dr Hancock will continue as CEO of Vocan following completion of the acquisition.

Dr. Jan Burian, Founder and CTO of Vocan, is a successful biochemist and molecular biologist with extensive knowledge and an exclusive skill set in fermentative API-grade research, development and production. He has been cited in numerous academic publications. Dr. Burian previously held a site directorship with Pfizer Canada where he was responsible for a vaccine manufacturing facility that relied on his advanced fermentation techniques.

Dr. Hancock and Dr. Burian first began collaborating over twenty years ago and together bring a unique combination of broad scientific know-how and skill as they get set to take Vocan's exclusive psilocybin production capabilities to commercial scale.

"We are honored and privileged to work with scientists of Dr. Hancock's and Dr Burian's caliber", Joel Shacker, Chief Executive Officer of the Company stated. "Combined with the Company's existing infrastructure, and the integration of its intellectual property related to psychedelic treatments and novel drug therapies, an acquisition of Vocan, and its talented research team, only furthers the Company development in the alternative psychedelics medicine market."

Terms of the LOI

Under the terms of the LOI, in consideration for all of the outstanding share capital of Vocan, the Company is expected to issue 23,500,000 common shares (the "Consideration Shares"), and 4,000,000 common share purchase warrants (the "Consideration Warrants"), to the existing shareholders of Vocan. Each Consideration Warrant will be exercisable to acquire an additional common share of the Company at a price of $0.30 for a period of twenty-four months.

In addition to the Consideration Shares, and the Consideration Warrants, the existing shareholders of Vocan will also be eligible to receive bonus payments of up to 5,000,000 common shares (the "Bonus Shares"). The Bonus Shares will be issuable in two tranches, of which 2,500,000 will be issuable upon the successful synthesis of psilocybin, and a further 2,500,000 will be issuable upon the filing of a patent application for such synthesis method in at least one jurisdiction.

It is anticipated that a portion of the Consideration Shares will be subject to the terms of a pooling arrangement, during which time they not be transferred or traded without the prior consent of the Company. The Consideration Shares will be released from the arrangement in tranches over a period of nine months following completion of the acquisition.

Completion of the acquisition of Vocan remains subject to a number of conditions, including the satisfactory completion of due diligence, receipt of any required regulatory approvals and the negotiation of definitive documentation. The acquisition cannot be completed until these conditions have been satisfied.

The Company is at arms-length from Vocan, and each of its shareholders. The acquisition of Vocan is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. No finders fees or commissions are payable in connection with the acquisition of Vocan. An administrative fee of 470,000 common shares is owing to a third-party consultant who will be assisting with completion of the acquisition.

About Core One Labs Inc.

Core One Labs Inc. is a research and technology company with a state-of-the-art cannabis production and packaging facility located in Southern California. The Company's technology produces infused strips (like breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. The Company holds an interest in walk-in medical clinics located in Vancouver and West Vancouver, British Columbia which maintain a database of over 200,000 patients combined. The Company intends to further develop its product offerings through research and development in these clinics, including the integration of intellectual property related to psychedelic treatments and novel drug therapies.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

SOURCE: Core One Labs Inc.

View source version on accesswire.com:

Copyright 2020 ACCESSWIRE. All Rights Reserved.